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Abstract
The effect of blocking VEGF activity in solid tumors extends beyond inhibition of angiogenesis. However, no studies have
compared the effectiveness of mechanistically different anti-VEGF inhibitors with respect to changes in tumor growth and
alterations in the tumor microenvironment. In this study we use three distinct breast cancer models, a MDA-MB-231
xenograft model, a 4T1 syngenic model, and a transgenic model using MMTV-PyMT mice, to explore the effects of various
anti-VEGF therapies on tumor vasculature, immune cell infiltration, and cytokine levels. Tumor vasculature and immune cell
infiltration were evaluated using immunohistochemistry. Cytokine levels were evaluated using ELISA and electrochemi-
luminescence. We found that blocking the activation of VEGF receptor resulted in changes in intra-tumoral cytokine levels,
specifically IL-1b, IL-6 and CXCL1. Modulation of the level these cytokines is important for controlling immune cell
infiltration and ultimately tumor growth. Furthermore, we demonstrate that selective inhibition of VEGF binding to VEGFR2
with r84 is more effective at controlling tumor growth and inhibiting the infiltration of suppressive immune cells (MDSC,
Treg, macrophages) while increasing the mature dendritic cell fraction than other anti-VEGF strategies. In addition, we
found that changes in serum IL-1b and IL-6 levels correlated with response to therapy, identifying two possible biomarkers
for assessing the effectiveness of anti-VEGF therapy in breast cancer patients.
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Introduction
Virchowfirstidentifiedalinkbetweeninflammationandcancerin
the late 1800s [1]. Since that time, the concept that chronic
inflammation in the tumor microenvironment contributes to tumor
progression has been validated in many types of cancer [1,2,3].
However, the underlying mechanisms for this connection remain
unclear. Solid tumor malignancies consist of a diverse population of
cells, including tumor cells, fibroblasts, endothelial cells and immune
cells [4,5]. It is now clear that chronically activated immune cells can
promote tumor growth and facilitate tumor survival. Macrophages
are typically the main inflammatory component, but a variety of
immune cells infiltrate tumors and can participate in tumor
promotion [6]. In general, these cells confer a worse prognosis in
many types of cancer, including breast cancer [7].
Vascular endothelial growth factor-A (VEGF) is a primary
stimulant for tumor angiogenesis, making it a critical target for
cancer therapy [8]. VEGF binds and activates VEGF receptor 1
(VEGFR1) and VEGFR2. Although the function of VEGFR2 in
tumor angiogenesis has been characterized thoroughly, the function
of VEGFR1 has not been well defined [9]. Clinically, elevated levels
of VEGF correlate with increased lymph node metastases and a
worse prognosis in breast cancer [10]. Bevacizumab (AvastinH,
Genentech), a humanized monoclonal antibody that binds human
VEGF and prevents VEGF from binding VEGFR1 and VEGFR2,
is approved for the treatment of metastatic HER2/NEU-negative
breast cancer [11]. The clinical success of bevacizumab has
bolstered the development and testing of agents that directly target
VEGF, selectively inhibit VEGFR1 or VEGFR2, or promiscuously
block both VEGF receptors as well as other receptor tyrosine
kinases [12,13]. Previously, we have shown that selective inhibition
of VEGF binding to VEGFR2 with a fully human monoclonal
antibody (r84) is sufficient for effective control of tumor growth in a
preclinical model of breast cancer [14]. However, few studies have
compareddirectlytheeffectivenessofdifferentanti-VEGFstrategies
in preclinical models.
The anti-tumor effect of angiogenesis inhibitors is due in part to
reduction of VEGF-induced angiogenesis [15]. Immune cells also
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7669express receptors for VEGF; however, the effect of anti-VEGF
therapy on the infiltration of immune cells into tumors has not been
fully characterized. VEGF is a major chemoattractant for inflam-
matory cells, including macrophages, neutrophils, dendritic cells
(DCs), myeloid-derived suppressor cells (MDSCs) and T-cells
[16,17,18,19,20,21]. In tumor xenograft models, anti-VEGF ther-
apy leads to a reduction in macrophage infiltration [14,16,22,23].
Recently, we found that selective inhibition of VEGF from binding
VEGFR2 with r84 resulted in decreased in MDSC infiltration and
increased neutrophil and mature dendritic cell infiltration in MDA-
MB-231 human breast cancer xenografts [14]. Like macrophages,
MDSCs (CD11b
+Gr1
+) are an important contributor to tumor
progression whereby, these cells secrete immunosuppressive media-
tors and induce T-lymphocyte dysfunction [24,25]. MDSCs express
VEGFR1 and VEGFR2 [6] and studies in non-tumor bearing
animals demonstrate that activation of VEGFR2 promotes MDSC
infiltration into the spleen [17]. VEGF is also important for monocyte
chemotaxis and is a key regulator of the differentiation and migration
of dendritic cells (DCs) [17,26]. In non-tumor bearing animals,
VEGFR1 activation inhibits stem cell differentiation to the dendritic
cell lineage whereas VEGFR2 activation decreases the number and
function of mature dendritic cells in the spleen [17]. Unlike other
myeloid cell types, increased tumor-infiltrating DCs is associated with
improved prognosis and specifically, the number of CD83
+ DCs has
been shown to inversely correlate with lymph node metastasis and
tissue expression of VEGF and TGF-b in human breast cancer
specimens [27]. CD4
+CD25
+FoxP3
+ regulatory T cells (Treg)
contribute to maintenance of immunologic self-tolerance. However,
the function of Treg as natural immune suppressors may also
contribute to the immune imbalance found in cancers [28].
Clinically, blood from patients with breast or pancreatic cancer has
an increased percentage of Treg compared to healthy individuals
[29]. Treg secrete immunosuppressive cytokines such as TGF-b and
IL-10, but little IFN-c [29]. Though TGF-b can induce peripheral
Treg, it is not required for the generation of a thymic-derived subset
of these cells. Recently, IL-2, IFN-cand TNF-ahave been implicated
in Treg generation [30,31,32]. However, the effect of anti-VEGF
therapy on Treg infiltration is unknown.
In the present study, we use three distinct preclinical models of
breast cancer to compare the effect of different anti-VEGF
therapies on breast cancer growth, vascular parameters, immune
cell infiltration and intra-tumoral cytokine levels. We found that
inhibition of VEGF receptor activation resulted in changes in
intra-tumoral levels of IL-1b and CXCL1 that correlate with
changes in immune cell infiltration. Furthermore, serum levels of
IL-1b and IL-6 correlate with tumor response to anti-VEGF
therapy and may be predictive clinical markers.
Results
Comparison of Anti-VEGF Strategies on MDA-MB-231
Tumor Growth and Angiogenesis
Anti-VEGF therapy has been validated clinically in many types
of cancer, including breast cancer [11,33]. However, few studies
have investigated whether differential blockade of the VEGF
pathway results in differential effects on tumor growth and the
tumor microenvironment in breast cancer. We studied the effect of
selectively blocking the VEGF pathway using the agents listed in
Table 1 in mice bearing established MDA-MB-231 human breast
tumor xenografts. The effect of therapy with all six agents was
evaluated after one and four weeks of drug exposure. After one
week of therapy, only tumors from mice treated with r84 or
bevacizumab were significantly smaller than control-treated
tumors (Fig. 1A). After four weeks of therapy, selective blockade
of VEGF binding to VEGFRs (r84; bevacizumab) and the RTKI
(sunitinib) significantly limited tumor growth compared to control
treatment (Fig. 1A). Tumors treated with agents that selectively
block VEGFR2 (RAFL-2) or both receptors (GU81) did not
control tumor growth compared to control IgG at the one and
four week time points. Tumor volume increased an average of
393% from day 31 (week 1) to day 52 (week 4) post tumor cell
injection (TCI) time in mice receiving a control IgG. Treatment
with r84, bevacizumab, RAFL-2, GU81, and sunitinib resulted in
mean tumor volume increases of 102, 244, 239, 224, and 109%,
respectively. Each of these inhibitors block VEGFR2 activity
(Fig. 1A). These results support the concept that selective
inhibition of VEGFR2 is adequate to control the growth of
human breast tumor xenografts.
To determine the effect of anti-VEGF therapy on angiogenesis,
we assessed microvessel density (number of vessels/100X field) and
vascular area (% positive fluorescent area/100X field) at the one
and four week time points (Fig. S1A). Percent change (D) in MVD
or vascular area was defined as week 4 MVD or vascular area/
mean week 1 MVD or vascular area. After one week of therapy,
only bevacizumab-treated tumors had significantly fewer vessels
(p,0.05) compared to control-treated tumors (Fig. 1B). However,
overall vascular area was decreased in tumors from animals
treated with bevacizumab, r84 and sunitinib (Fig. 1C); indicating
vessel size was decreased after anti-VEGF therapy. After four
weeks of therapy (Fig. 1B), only r84 and bevacizumab reduced
microvessel density compared to control IgG (p,0.001). Interest-
ingly, r84 prevented an increase in MVD from week 1 to week 4 of
therapy, while MVD increased in all other treatment conditions
(Fig. 1B; % D in MVD). However, tumors from all anti-VEGF
therapies, except RAFL-2 had an increase in vascular area over
the course of therapy (Fig. 1C; % D in vascular area). In
comparing the anti-angiogenic activity of these agents, we found
that selectively blocking VEGF from binding VEGFR2 (r84) was
as or more effective than all other anti-VEGF strategies in
decreasing MVD and vascular area in MDA-MB-231 orthotopic
xenografts.
VEGF Is an Important Cytokine for Immune Cell
Infiltration in MDA-MB-231 Human Breast Cancer
Xenografts
Previously, we have shown a reduction in macrophage and
MDSC infiltration and an increase in neutrophil infiltration into
xenografts following anti-VEGF therapy [14,16,22]. Surprisingly,
after one week of therapy, selective blockade of VEGFR2 with
Table 1. Anti-VEGF Agents
a.
Agent Class Target Target Species
r84 Human Ab VEGF
(blocks VEGFR2 only)
Mouse & Human
mcr84 Murine chimeric
Ab
VEGF
(blocks VEGFR2 only)
Mouse & Human
bevacizumab Humanized Ab VEGF
(blocks VEGFR1 and VEGFR2)
Human
RAFL-2 Rat Ab VEGFR2 Mouse
GU81 Peptoid VEGFR1/2 Mouse & Human
sunitinib Small molecule VEGFR1/2, cKit, PDGFRb Mouse & Human
aAb: antibody;VEGF:Vascularendothelialgrowthfactor; VEGFR1:VEGFreceptor1;
VEGFR2: VEGF receptor 2; PDGFRb: Platelet-derived growth factor receptor b.
doi:10.1371/journal.pone.0007669.t001
AntiVEGF Alters Immune Profile
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compared with control treated animals (RAFL-2: 78.8610.5 vs
control: 15.464.5 cells/200X field; p,0.01; Fig. 2A; Fig. S1B).
However, after four weeks of therapy, all anti-VEGF agents
reduced macrophage infiltration (Fig. 2A). Neutrophil infiltration
was examined using the anti-neutrophil antibody, 7/4. Acute
selective inhibition of VEGFR2 (RAFL-2) induced neutrophil
accumulation into tumors (Fig. 2B; Fig. S1C). While chronic
inhibition of VEGFR2 activation by r84 and RAFL-2, but not
other strategies, resulted in increased neutrophil accumulation in
tumors (Fig. 2B). Next, we investigated the effect of anti-VEGF
therapy on MDSC infiltration (CD11b
+Gr1
+ cells) into tumors.
Bevacizumab treatment resulted in MDSC accumulation after 1
and 4 weeks of therapy, although the increase was only significant
after 1 week (Fig. 2C; Fig. S1D). Sunitinib on the other hand
reduced the number of MDSC cells at both time points although
again this was only significant after one week of therapy (Fig. 2C).
GU81, which binds both VEGFR1 and VEGFR2 had little effect
on MDSC numbers after 1 week of therapy; however at the 4 week
time point, there was a significant increase in MDSC infiltration
compared to control-treated animals (Fig. 2C). r84 and RAFL-2
had no discernable effect on MDSC numbers after one week of
therapy although each reduced MDSC infiltration after 4 weeks of
treatment (Fig. 2C; Fig. S1D). How VEGF governs MDSC
recruitment into tumors is unclear. Our data suggests that
blockade of VEGFR1 and VEGFR2 (e.g., bevacizumab and
GU81) can induce an increase in MDSC infiltration, while
selective blockade of VEGFR2 limits MDSC accumulation in this
xenograft model of breast cancer.
Mouse Chimeric r84 Delays Tumor Growth and Improves
the Immune Profile in Inflammatory 4T1 Breast Tumors
Growth of 4T1 tumors cells in the mammary fat pad of BALB/c
mice is an inflammatory model of breast cancer in which immune
cells comprise 40-50% of the overall tumor mass [34,35]. To extend
our previous observations, we performed similar experiments
Figure1.Anti-tumorandanti-vasculareffectsofVEGF pathwayinhibition in MDA-MB-231xenografts. MDA-MB-231humanbreast cancer
cells (5610
6) were injected into the mammary fat pad of SCID mice. Treatment with control IgG, bevacizumab (bev), r84, or RAFL-2 (250 mg twice
weekly), GU81 (120 mg daily), sunitinib (200 mg daily) was initiated in established tumors (,150 mm
3) on day 24 post tumor cell injection (TCI) and
continued for 1 (Week1)or 4 (Week4)weeks.(A)Meantumorvolumeafter1 (n=12/group) and4 (n=4/group) weeksoftherapy isdisplayed.Themean
percent change in tumor volume from 1 to 4 weeks of therapy is displayed as a scatter plot and was determined by dividing the tumor volume from
individual mice at after 4 weeks of therapy by the mean tumor volume of the group after 1 week of therapy (n=4/group/timepoint). (B–C) Tumor
sections were analyzed by immunofluorescence using MECA-32, an endothelial cell marker for microvessel density (MVD, B) and vascular area (C). Data
are displayed as mean6SEM and represents 5 images (Total magnification, 100X) per tumor and three tumors per group. Images were analyzed using
Elements software. *p=0.05, **p=0.01, ***p,0.001.
doi:10.1371/journal.pone.0007669.g001
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PCR, we demonstrate that 4T1 cells express VEGFR1 but not
VEGFR2 in vitro (Table S1). For in vivo studies, mice with small but
established tumors were treated for 1 or 3 weeks with a control IgG,
a mouse chimeric version of r84 (mcr84), GU81, or sunitinib
(Table 1). As seen in the MDA-MB-231 model, after one and three
weeks of therapy, inhibition of mouse VEGF binding to VEGFR2
(mcr84) significantly reduced tumor growth compared to control
IgG (Fig. 3A). Interestingly, GU81 controlled tumor growth after
one and three weeks, while sunitinib had little effect on tumor
volume or weight at either time point (Fig. 3A).
Though mcr84 and GU81 limited tumor growth after one week
of therapy, tumors from GU81-treated animals had increased
MVD and vascular area (Fig. 3C and D, week 1). In contrast, after
three weeks of therapy, tumors from all treatment groups had a
reduction in MVD compared to control (Fig. 3C, week 3; Fig. 4A).
Unpredictably, tumors from animals treated with mcr84 had
increased vascular area compared to control-treated tumors
(4.37%60.85 vs 1.67%60.13, respectively; p,0.05) after three
weeks of therapy (Fig. 3D). However, all three agents prevented an
increase in MVD from week 1 to week 3 of therapy (Fig. 3C; % D
in MVD). These surprising vascular changes following mcr84 and
GU81 therapy were validated using two additional endothelial cell
markers, endomucin and CD31 (Fig. S2A–C).
Similar to MDA-MB-231 tumors, inhibition of VEGF resulted
in reduced macrophage infiltration (CD68
+ cells). This was evident
with mcr84 at both time points. GU81 and sunitinib also reduced
macrophage numbers after three weeks of therapy although the
changes did not reach statistical significance (Fig. 4B, Fig. 5A). We
also found that neutrophil infiltration (7/4
+ cells) was reduced
significantly following chronic therapy with GU81 or sunitinib
(Fig. 4C, Fig. 5B).
Tregs were identified by the co-expression of CD25 and FoxP3.
Though we did not see any significant changes in Treg infiltration
after one week of anti-VEGF therapy (Fig. 5C), chronic anti-VEGF
therapy inhibited the infiltration of Treg into tumors compared to
control IgG (Fig. 4E, Fig. 5C). In the MDA-MB-231 model, we
found a significant increase in MDSCs in tumors treated with
chronic GU81 (Fig. 2C). However, in the 4T1 breast cancer model,
we found a significant reduction in MDSC infiltration in all anti-
VEGF groups at both time points (Fig. 4F, Fig. 5D).
Previously, we identified an increase in CD83
+CD11c
+ mature
dendritic cells in MDA-MB-231 tumors treated with r84 [14]. We
found a similar effect in the 4T1 model, whereby there was an
overall decrease in CD11c
+ cells in all treatment groups after one
week of therapy (Fig. 5E). However, when we looked at the
number of CD83
+CD11c
+ mature dendritic cells (Fig. 4D, Fig. 5E),
tumors from animals treated with mcr84 had a significant increase
in this population of cells compared to all other treatment groups.
Furthermore, when we specifically analyzed the CD11c
+ popula-
tion of cells, we found that approximately 48% of dendritic cells
within mcr84 tumors expressed CD83, whereas only 14.8, 27.8
and 16.8% of dendritic cells in control, GU81 or sunitinib,
respectively, expressed CD83 (Fig. 5E; p,0.001).
Effect of Anti-VEGF Therapy on Immune Cell Infiltration
in the Transgenic MMTV-PyMT Breast Tumor Model
The MMTV-PyMT transgenic mouse expresses the polyoma-
virus middle T antigen driven by the MMTV-LTR promoter [36].
Polyomavirus middle T oncogene expression results in the
generation of multifocal mammary carcinomas in 100% of female
mice. We treated 52 day old transgenic MMTV-PyMT females
with control IgG, mcr84, GU81 or sunitinib for four weeks
(Table 1). Similar to the MDA-MB-231 model, we found that
mcr84 controlled tumor growth after four weeks of therapy
compared to control-treated tumors (Fig. S3A). Tumors from
mcr84-treated animals had a decrease in vascular area and
macrophage infiltration (CD11b
+Gr1
2 cells) compared to control-
treated tumors (Fig. S3B, C) and an increase in neutrophils
(CD11b
2Gr1
+ cells; Fig. S3D). Additionally, mcr84-treated
tumors also had a significant reduction in MDSC and Treg
infiltration compared to control, GU81, and sunitinib treated
tumors (Fig S3E, F).
With these studies, we have extended our previous observations
[14] into an immunocompetent model system and have further
validated that VEGF is an important cytokine that regulates
immune cell trafficking into breast tumors.
Tumor Cytokine Profile Changes Induced by Anti-VEGF
Therapy
To address some of the differences we found in immune cell
infiltration with anti-VEGF therapy, we analyzed intra-tumoral
cytokine levels in tumor lysates from the various treatment groups
in the MDA-MB-231 and 4T1 models (Tables S2 & S3). MDSC
accumulation is driven by many factors, including VEGF and IL-
1b [17,37,38]. Given that there were differences in MDSC
infiltration following different anti-VEGF therapies, we hypothe-
sized that this may be due to aberrations in intra-tumoral IL-1b
levels. In the MDA-MB-231 model, we found that inhibition of
Figure 2. Inhibition of VEGF receptor activation utilizing
different blocking strategies results in variations in immune
cell infiltration in MDA-MB-231 human breast cancer xeno-
grafts. (A–C) Tumor sections were analyzed by immunofluorescence
using F4/80, a macrophage marker, (A), and 7/4, a neutrophil marker (B).
Tumor sections were evaluated by immunofluorescence for myeloid-
derived suppressor cells (MDSCs, C) defined as the number of cells that
express CD11b and Gr1 per 200X field. Data are displayed as
mean6SEM and represents 5 images (Total magnification, 200X) per
tumor and three tumors per group. Images were overlayed and
analyzed using Elements software. *p=0.05, **p=0.01.
doi:10.1371/journal.pone.0007669.g002
AntiVEGF Alters Immune Profile
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binding (bevacizumab) or receptor activation (GU81) resulted in
significant increases in MDSC infiltration (Fig. 2C). In this model,
intra-tumoral IL-1b levels were increased significantly following
one week of bevacizumab therapy and four weeks of GU81
therapy (Table 1; Fig. 6A). By linear regression analysis, we found
that changes in IL-1b levels as a result of anti-VEGF therapy were
highly correlative with changes in MDSC infiltration at the one
and four week time points (Fig. 6B).
In the 4T1 model tumors from mcr84-treated animals had
increased levels of IL-1b after three weeks of therapy (Fig. 6C).
Furthermore, following one week of therapy we found a trend in
which increases in IL-1b correlated positively with MDSC
infiltration (Table 2). However, after chronic anti-VEGF therapy
(three week time point), increases in intra-tumoral IL-1b levels
correlated negatively with changes in intra-tumoral MDSCs
(Fig. 6D; Table 2). These results suggest that IL-1b has a bi-
modal effect on MDSC migration such that IL-1b concentrations
#5 pg/mg or $50 pg/mg result in reduced recruitment of
MDSCs. We also evaluated intra-tumoral levels of IL-6, a
downstream effector of IL-1b previously shown to be important
for MDSC infiltration [37], and found that levels of this cytokine
did not correlate with MDSC number after 3 weeks of therapy.
This indicates that IL-6 is not the downstream mediator of IL-1b-
Figure 3. Anti-VEGF therapy delays tumor growth and reduces microvessel density in the inflammatory 4T1 breast cancer model. (A–
B) 4T1 murinebreast cancer cells (1610
5) were injected into the mammary fatpad of BALB/c mice. Treatment with 250 mg twice weekly of eithercontrol
IgGor mcr84, 120 mg daily GU81 or 200 mg daily sunitinib was initiated in establishedtumors (,15 mm
3) on day 12 post tumorcell injection (TCI; arrow)
and continued for 1 (A) or 3 (B) weeks (n=4/group/timepoint). Tumor volumes were measured twice weekly and mean tumor volume +/2 SEM is
displayed. (C–D) Tumor sections were analyzed by immunofluorescence using MECA-32, an endothelial cell marker at the one and three week time
points for microvessel density (MVD, C) and vascular area (D). Data are displayed as mean6SEM and represents 5 images (Total magnification, 100X) per
tumor and three tumors per group. Images were analyzed using Elements software. *p=0.05, **p=0.01, ***p,0.001.
doi:10.1371/journal.pone.0007669.g003
AntiVEGF Alters Immune Profile
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suggests that another downstream target of IL-1b may modulate
MDSC infiltration in this model.
CXCL1 (KC, GRO) is expressed by macrophages, neutrophils,
endothelial cells and has neutrophil chemoattractant activity [39].
IL-1b can induce CXCL1 expression via a different mechanism
than IL-6 [40]. In 4T1 tumors, we found that changes in CXCL1
levels were correlative with changes in IL-1b after one and three
weeks of anti-VEGF therapy (Table 2, Table S3). Furthermore,
changes in CXCL1 levels with anti-VEGF therapy negatively
correlate with changes in MDSC infiltration at both time points
(Fig. 7A; Table 2), suggesting an alternative mechanism for MDSC
recruitment in the presence of anti-VEGF therapy and increased
levels of IL-1b.
Previously, we have shown that mice treated with r84 have no
detectable level of free VEGF in serum [14]. Therefore, we sought
to investigate an alternative mechanism for the increased vascular
area seen in 4T1 tumor-bearing animals treated chronically with
mcr84 (Fig. 3D). Though VEGF is the primary stimulant for tumor
angiogenesis, IL-1b can also stimulate in vitro endothelial cell
migration and proliferation [41] and angiogenesis in mouse models
of cancer via up regulation of VEGFR2 [42,43]. mcr84-treated
Figure 4. Representative immunofluorescence images of microvessel density and immune cell infiltration in the 4T1 model. Tumor
sections from mice treated with the indicated anti-VEGF agent were analyzed by immunofluorescence using MECA-32, an endothelial cell marker (A),
CD68, a macrophage marker (B), and 7/4, a neutrophil marker (C). Tumor sections were evaluated by immunofluorescence for mature dendritic cells
by co-localization (box) of CD83 and CD11c (D); Treg by co-localization of CD25
+and FoxP3
+ cells (E); and myeloid-derived suppressor cells defined as
the number of cells that express CD11b and Gr1 per 200X field (F). The inset on each picture in row D is a magnified view of co-localization of CD83
and CD11c. Representative pictures of control and anti-VEGF treated tumors are displayed. Total magnification, 200X; except for Meca-32 staining
(100X), scale bar, 100 mm. Images were overlayed and analyzed using Elements software. Quantitation of signal intensity is shown in Figures 3 and 5.
doi:10.1371/journal.pone.0007669.g004
AntiVEGF Alters Immune Profile
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compared to control-treated tumors (Fig. S2C). Furthermore, we
found by linear regression analysis, that increases in vascular area
seen with anti-VEGF therapy correlated with changes in IL-1b and
IL-6 (Fig. 7B & C; Table 2), suggesting an alternative pathway for
angiogenesis in the presence of anti-VEGF therapy.
Figure 5. mcr84 reduces immune suppressor cells and increases mature dendritic cell infiltration in the inflammatory 4T1 breast
cancer model. (A–B) Tumor sections were analyzed by immunofluorescence at the one and three week time points using CD68, a macrophage
marker (A), and 7/4, a neutrophil marker (B). (C–E) Tumor sections were evaluated by immunofluorescence for (C) Tregs, colocalization of CD25
+ and
FoxP3
+ (D) and MDSCs, colocalization of CD11b
+ and Gr1
+. Dendritic cells were characterized using CD11c
+ (total DCs), mature dendritic cells, defined
as colocalization of CD83 and CD11c and % of CD11c
+ cells that were CD83
+ (Week 1 only). Data are displayed as mean6SEM and represents 5
images (Total magnification, 200X) per tumor and three tumors per group. Images were overlayed and analyzed using Elements software. *p=0.05,
**p=0.01, ***p,0.001 vs control; #p=0.05, ###p,0.001 vs mcr84.
doi:10.1371/journal.pone.0007669.g005
AntiVEGF Alters Immune Profile
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T cells (Treg) in the tumor microenvironment is not completely
understood. Though TGF-b can induce peripheral Treg, it is not
required for the generation of a thymic-derived subset of these
cells. Recently, IL-2, IFN-c and TNF-a have been implicated
in Treg generation [30,31,32]. In this study we found that only
IFN-c levels correlate with Treg infiltration during both acute and
chronic therapy, indicating IFN-c may direct the development or
migration of Treg in the face of anti-VEGF therapy (Table 2).
Identification of Potential Biomarkers of Response
Given the changes we observed in inflammatory cytokines in
response to various anti-angiogenesis strategies, we sought to
investigate whether changes in serum levels of these cytokines
would correlate with tumor progression. High levels of serum IL-
1b and IL-6 levels correlated with delayed tumor progression in
animals bearing 4T1 tumors treated with mcr84 and GU81,
whereas low levels of these cytokines corresponded to tumor
progression (Fig. 8A–C). However, low levels of IL-6 in the sera of
sunitinib-treated animals correlated with tumor progression
(Fig. 8D). These findings highlight the importance of the inflam-
matory cytokine profile in tumor progression and identify possible
biomarkers of response to r84 or other anti-VEGF agents in breast
cancer.
Discussion
In this report, we provide data that demonstrate the
effectiveness of anti-VEGF therapy as a modulator of immune
cell infiltration, and intra-tumoral and serum cytokine levels in
multiple preclinical models of breast cancer. It is becoming
increasing clear that the effect of anti-VEGF agents extends
beyond the inhibition of angiogenesis, as many immune cells
express VEGFRs, including macrophages, neutrophils, MDSCs,
DCs and T-cells [6,17,26,44,45]. We and others have shown a
reduction in macrophages in tumors from animals treated with
anti-VEGF therapy [14,16,23]. In preclinical models of colon
cancer, sunitinib treatment reduced the accumulation of MDSCs
and plasmacytoid dendritic cells in tumors compared to control
treatment [20]. In metastatic renal cell carcinoma patients,
sunitinib therapy reduced the level of circulating MDSCs and
reduction in MDSCs in response to sunitinib therapy correlated
with an increase in T-cell IFN-c production [18]. These studies
suggest that sunitinib or other anti-VEGF therapies function as
modulators of antitumor immunity. Here, we demonstrate that
inhibition of VEGF binding to VEGFR2 with r84 is more effective
than other anti-VEGF strategies in controlling breast tumor
growth and the infiltration of immune suppressor cells.
Using the MDA-MB-231 human breast cancer model, we
demonstrate that inhibition of VEGF binding to VEGFRs with
bevacizumab or r84 effectively controls tumor growth (Fig. 1A).
Furthermore,onlyselectiveinhibitionofVEGFbindingtoVEGFR2
with r84 is able to prevent an increase in MVD from week 1 to week
4 of therapy (Fig. 1B). Interestingly, when these experiments were
repeated using the immunocompetent 4T1 inflammatory breast
cancer model, mcr84 and the VEGFR1 & VEGFR2 binding
peptoid, GU81, were able to control tumor growth (Fig. 3A and B).
Though mcr84 was able to reduce MVD as seen in the MDA-MB-
231 model, 4T1 tumors from animals treated with chronic mcr84
had an increase in vascular area compared to control (Fig. 3C and
D). In an effortto explainthis increase invascular area,we evaluated
intra-tumoral cytokine levels in tumors from all treatment groups at
the one and three week time points (Table S3). Though hypoxia and
VEGF are the main angiogenic stimuli, other cytokines, including
IL-1b, IL-6 and TNF-a can induce angiogenesis [42,43,46,47]. For
example, in cardiac myocytes IL-1b increases VEGFR2 expression
[43]. In mcr84-treated tumors, we found increased levels of IL-1b
and VEGFR2 compared to control-treated tumors (Fig. 6C, Fig.
S2C). By linear regression analysis, increases in intra-tumoral IL-1b
following anti-VEGF therapy correlated with increased vascular
area (Fig. 7B). VEGFR2 is the main receptor responsible for VEGF-
induced angiogenesis and is activated by VEGF-A, C, or D [48,49].
It is plausible that VEGF-C/D may bind to increased levels of
VEGFR2, resulting in increased VEGFR2 phosphorylation and
signaling. Increased VEGFR2 signaling can then promote the
increased vascular area observed in mcr84- treated tumors.
The effects of anti-VEGF therapy extend beyond its effects on
tumor blood vessels. In both the MDA-MB-231 and 4T1 models,
chronic anti-VEGF therapy reduced macrophage infiltration in all
treatment groups. In non-tumor bearing animals, monocyte and
macrophage migration is driven in part by placental growth factor
(PlGF), VEGF and VEGFR1 [50]. However, we have shown
previously that VEGFR2 is expressed on macrophages from
tumor-bearing animals, and is the dominant receptor driving
Figure 6. Changes in intra-tumoral IL-1b levels following anti-
VEGF therapy correlate with intra-tumoral MDSCs. (A) MDA-MB-
231 intra-tumoral IL-1b levels after one and four weeks of anti-VEGF
therapy were determined by electrochemiluminescence. (B) By linear
regression analysis, changes in MDA-MB-231 intra-tumoral IL-1b levels
following anti-VEGF therapy positively correlate with intra-tumoral
CD11b
+Gr1
+ (MDSCs) after one and four weeks of therapy. Each dot
represents the mean IL-1b and MDSC for each treatment group. (C) 4T1
intra-tumoral IL-1b levels after three weeks of anti-VEGF therapy were
determined by electrochemiluminescence. (D) By linear regression
analysis, changes in 4T1 intra-tumoral IL-1b levels following anti-VEGF
therapy negatively correlate with intra-tumoral CD11b
+Gr1
+ (MDSCs)
after three weeks of therapy. Each dot represents the mean IL-1b and
MDSC for each treatment group. *p=0.05
doi:10.1371/journal.pone.0007669.g006
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[14,16]. Therefore, the reduction in macrophage migration seen
following anti-VEGF therapy is likely due to the inhibition of
VEGFR2 signaling (Fig. 2A; Fig. 5A). Interestingly, the inhibition
of both VEGFR1 and VEGFR2 activation with bevacizumab,
GU81, or sunitinib did not reduce macrophage infiltration better
than agents that inhibited the activation of VEGFR2 alone (r84 or
RAFL-2).
Neutrophils are often described as ‘first responders’ and have
been shown to be capable of mediating the angiogenic switch in
engineered animal models of cancer [23,51]. The mechanism
underlying the increase in 7/4
+ cells after anti-VEGF therapy is
unclear. VEGF can stimulate neutrophil migration in vitro via
VEGFR1 activation [19]. Furthermore, these cells were shown to
express VEGFR1 and VEGFR2 by RT-PCR, suggesting that even
though VEGFR2 is present, VEGFR1 is the primary receptor
mediating VEGF-induced migration of these cells. In support of
this, we have previously shown an increase in neutrophil
infiltration in r84-treated tumors [14]. In this study, we have
further characterized the effect of anti-VEGF therapy on
neutrophil infiltration utilizing an immunocompetent model of
breast cancer. In the 4T1 model, tumors from animals treated with
agents that block VEGFR1 activation (GU81 and sunitinib) had
reduced neutrophil infiltration compared to control-treated
tumors. In contrast, tumors from animals treated with mcr84,
where VEGFR1 signaling was intact, had an increase in
neutrophil infiltration (Fig. 5B), suggesting that VEGFR1 is the
dominant receptor involved in VEGF-mediated neutrophil
migration in tumor-bearing animals.
VEGF is a key mediator in the development and maturation of
dendritic cells [17]. Activation of VEGFR1 on dendritic cells
inhibits hematopoetic stem cell differentiation along the dendritic
cell lineage, whereas VEGFR2 is important for dendritic cell
maturation [17]. Previously, using the MDA-MB-231 model, we
found an increase in mature dendritic cells in animals treated with
r84, but not bevacizumab [14]. In this study, we demonstrate that
this effect is seen after only one week of therapy, as inhibition of
VEGF binding to VEGFR2 with mcr84 reduced the number of
total dendritic cells, while increasing the mature fraction of these
cells (Fig. 5E). Though the antigen presenting ability of these cells is
not known, in human breast cancer specimens, increased CD83+
dendritic cells is associated with an improved prognosis [52].
The role of VEGF in myeloid-derived suppressor cells (MSDC)
differentiation and migration has been characterized in recent
Table 2. Changes in 4T1 intra-tumoral cytokine levels with anti-VEGF therapy correlate with changes in immune cell infiltration
a.
Week 1 Week 3 3
r
2 IL-1b IL-6 CXCL1 TNF-a IFN-c IL-2 r
2 IL-1b IL-6 CXCL1 TNF-a IFN-c IL-2
IL-6 0.825 IL-6 0.818
CXCL1 0.834 0.952 CXCL1 0.945
TNF-a 0.967 0.804 0.882 TNF-a 0.668 0.964
IFN-c 0.959 0.934 0.953 0.961 IFN-c
IL-2 0.978 0.899 0.858 0.916 0.966 IL-2
IL-4 0.901 0.75 0.647 0.767 0.819 0.936 IL-4
IL-10 0.884 0.865 0.743 0.763 0.866 0.955 IL-10
MDSC 0.741 0.937 0.793 0.818 0.858 MDSC 0.911 0.418 0.986
Treg 0.964 0.671 0.725 0.956 0.878 0.891 Treg 0.138 0.831 0.305
Vascular
area
Vascular
Area
0.845 0.894 0.642
aData are displayed as r
2 as determined by Pearson correlation test; p,0.075 for all bolded values. Values in italics indicate significant negative correlation; values in
bold indicate a significant positive correlation. For example, as graphically displayed in Figure 5D, as IL-1b levels increase following three weeks of anti-VEGF therapy
(week 3, column1) MDSCs infiltration decreases (row 8; r
2=0.911)
doi:10.1371/journal.pone.0007669.t002
Figure 7. CXCL1, IL-1b, and IL-6 are differentially related to MDSC infiltration and vascular area in 4T1 tumors following anti-VEGF
therapy. (A–C) Intra-tumoral IL-1b, CXCL1 and IL-6 were determined by electrochemiluminescence and ELISA. (A) Changes in intra-tumoral CXCL1
levels following anti-VEGF therapy negatively correlate with intra-tumoral CD11b
+Gr1
+ (MDSCs) after three weeks of therapy. (B–C) Changes in intra-
tumoral IL-1b (B) and IL-6 (C) positively correlate with vascular area after chronic anti-VEGF therapy. Each dot represents the mean cytokine level for
each treatment group. N=4/grp, assayed in duplicate.
doi:10.1371/journal.pone.0007669.g007
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immunosuppressive cells are increased in the blood, spleen and
tumors [18,20,53]. Many factors induce MDSC expansion and
activation, including VEGF, IL-1b, and IL-6, making these
attractive targets for MDSC inhibition. In this study, we reveal
an interesting connection between these cytokines in mediating
MDSC infiltration into tumors. In MDA-MB-231 tumors,
treatment with anti-VEGF agents that block both VEGFR1 and
VEGFR2 (bevacizumab and GU81), but not other receptor
tyrosine kinases resulted in increased intra-tumoral IL-1b levels
and MDSC accumulation (Fig. 2C, Fig. 6A). It is interesting to
note that sunitinib, which also blocks both VEGFR1 and
VEGFR2 signaling, does not result in increased IL-1b and MDSC
accumulation. This is likely due to the fact that sunitinib also
blocks PDGFRb, GSF-1R, Flt-3, and cKit, any of which may be
important for increased expression of IL-1b. Furthermore,
changes in IL-1b levels in response to anti-VEGF therapy were
highly correlative with changes in MDSC infiltration at the one
and four week time-points (Fig. 6B), indicating that IL-1b is a key
cytokine mediating the infiltration of MDSCs following anti-
VEGF therapy. Interestingly, in the 4T1 immunocompetent
model of breast cancer, changes in intra-tumoral IL-1b levels
correlate negatively with changes in MDSC infiltration after three
weeks of therapy (Fig. 6D, Table 2), where increases in IL-1b
following treatment with mcr84 were associated with reduced
MDSC infiltration. These findings indicate a possible bimodal role
of IL-1b in MDSC infiltration, where a low level of IL-1b induces
MDSC infiltration and increased levels following anti-VEGF
therapy inhibit MDSC infiltration.
MDSCs do not express receptors for IL-1b; however, they do
express receptors for IL-6, which is capable of inducing MDSC
infiltration in the absence of IL-1b signaling [38]. Therefore, we
investigated other cytokines that may be involved in regulating
immune cell recruitment. Similar to IL-1b, tumors from animals
treated chronically with mcr84 had increased IL-6 and CXCL1
levels. However, only changes in CXCL1, not IL-6, correlated
negatively with changes in MDSC infiltration, as seen with IL-1b
(Fig. 7A, Table 2). Therefore, we propose that CXCL1 is an
inhibitor of MDSC infiltration subsequent to markedly increased
IL-1b levels following anti-VEGF therapy.
Treg are immune suppressor cells that maintain peripheral
tolerance [28]. Like MDSCs, these cells are increased in the blood
and tumors of cancer patients and mouse models of cancer [28].
The generation of Treg is a complicated process that involves
many cytokines, such as IL-2, TGF-b, IFN-c and TNF-a
[30,31,32]. Though acute anti-VEGF therapy did not affect Treg
infiltration, we found reduced levels of Treg after chronic anti-
VEGF therapy in all treatment groups (Fig. 4E; Fig. 5C).
Furthermore, only changes in intra-tumoral IFN-c levels corre-
lated with changes in Treg infiltration, further confirming its
importance in Treg infiltration/generation (Table 2).
Finally, having demonstrated changes in intra-tumoral cytokine
levels and immune cell infiltration with anti-VEGF therapy, we
looked at serum levels of IL-b and IL-6, as potential biomarkers of
response to anti-VEGF therapy. For animals treated with mcr84
or GU81, we found that decreases in serum levels of IL-1b and IL-
6 were highly correlative with changes in tumor size in the
presence of anti-VEGF therapy (Fig. 8A–C). Interestingly,
increases in serum IL-6 levels in sunitinib-treated animals
correlated with increases in tumor size, suggesting different
mechanisms for the cytokine aberrations seen between selective
versus broad spectrum anti-VEGF strategies (Fig. 8D).
In conclusion, we have demonstrated differences in the ability of
anti-VEGF therapy to affect tumor vasculature and modulate
immune cell infiltration, intra-tumoral and serum cytokine levels
depending on the mechanism of VEGF inhibition. We have
demonstrated that selective inhibition of VEGF binding to
VEGFR2 with r84 is effective at controlling tumor growth,
inhibiting the infiltration of suppressive immune cells (MDSC,
Treg, macrophages) while increasing the mature fraction of
dendritic cell infiltrates. Furthermore, we have identified two
possible biomarkers (IL-1b and IL-6) for assessing the efficacy of
anti-VEGF therapy in breast cancer patients.
Materials and Methods
Cell Lines, Culture Conditions
The human breast carcinoma cell line MDA-MB-231 and
murine breast carcinoma cell line 4T1 were obtained from ATCC
(Manassas, VA). Cells were maintained at 37uC in a mixture of 5%
CO2 and 95% air in Dulbecco’s minimal essential medium
(DMEM, Invitrogen; Carlsbad, CA; MDA-MB-231 cells) or
RPMI 1640 (Invitrogen, Carlsbad, CA; 4T1 cells) supplemented
with 10% fetal calf serum (Gemini Bio-Products, Woodland, CA).
Cell lines were confirmed to be pathogen free and human cell lines
were genotyped to confirm origin prior to implantation into
animals.
Animal Tumor Models
6–8 week old female NOD/SCID mice or BALB/c were
purchased from an on-campus supplier. The MMTV-PyMT
transgenic mice in the FVB background (The Jackson Laboratory,
Bar Harbor, ME) express the polyomavirus middle T antigen
driven by the MMTV-LTR promoter [36]. Polyomavirus middle
T oncogene expression results in the generation of multifocal
mammary carcinomas in 100% of female mice, followed by
progression to pulmonary metastases in the vast majority of
animals. Only female transgenic mice were used in these
experiments and were obtained by breeding transgenic male mice
Figure 8. Identification of potential biomarkers of response.
Serum levels of IL-1b and IL-6 were determined by electrochemilumines-
cence and ELISA, respectively from animals treated with anti-VEGF
therapy bearing 4T1 tumors. Change (D) in tumor size was calculated as
week three tumor weight/mean week one tumor weight for each
individual therapy group. (A-C) By linear regression analysis, changes in
serum levels of IL-1b (A) and IL-6 (B,C) negatively correlate with D in
tumor size for animals treated with mcr84 and GU81. (D) Changes in IL-6
levels with sunitinib therapy positively correlate with D in tumor size.
doi:10.1371/journal.pone.0007669.g008
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transgene expression by PCR analysis. Animals were housed in a
pathogen free facility and all animal studies were performed on a
protocol approved by the IACUC at the University of Texas
Southwestern Medical Center. 5610
6 MDA-MB-231 or 1610
5
4T1 cells were injected into the mammary fat pad (MFP) of SCID
or BALB/c mice, respectively using previously described tech-
niques [22,54]. Caliper measurements were performed twice
weekly and tumor volume was calculated as D6d
260.52, where D
is the long diameter and d is the perpendicular short diameter.
Anti-VEGF Therapy (Table 1)
Bevacizumab (AvastinH, Genentech, South San Francisco, CA)
was purchased from the clinical pharmacy at UT-Southwestern.
r84 and mouse chimeric r84 (mcr84) were provided by Peregrine
Pharmaceuticals, Inc (Tustin, CA). The production and full
characterization of r84, a human IgG1 specific for VEGF-A will
be described in detail in a forth-coming manuscript (Sullivan et al).
The hybridoma producing RAFL-2, a rat IgG specific for
VEGFR2 was obtained from Dr. Philip Thorpe and was produced
and purified in our laboratory as described [55]. GU81, a peptoid
that binds and specifically inhibits VEGFR1 and VEGFR2 was
produced as described previously [56,57,58,59]. Sunitinib, a
receptor tyrosine kinase inhibitor which inhibits VEGFR1,
VEGFR2, PDGFRb, c-kit, Flt-3, and c-Ret was purchased from
LC laboratories (Woburn, MA).
Therapy was initiated on day 26 post tumor cell injection for
MDA-MB-231 experiments or day 12 for 4T1 experiments, when
tumor volume reached approximately 150 mm
3 or 15 mm
3,
respectively. Therapy in the MMTV-PyMT model was initiated
when the mice reached 8 weeks of age. Animals were randomized
to receive intraperitoneal injection of IgG control, r84, bevacizu-
mab, or RAFL-2 (250 mg of the designated IgG) twice weekly
(Tuesday & Friday), GU81 (120 mg daily by intraperitoneal
osmotic pump; Alzet, Cupertino, CA), or sunitinib (200 mg/day
by oral gavage). Animals were sacrificed at various time points post
initiation of therapy: 1 week (MDA-MB-231 (n=4/group) and
4T1 models (n=6/group)), 3 weeks (4T1 model, n=4/group) or 4
weeks (MDA-MB-231 and MMTV-PyMT models; n=4/group).
Tumor weights were determined at the time of sacrifice and
necropsy.
PCR
RNA was prepared using TRIzol (Invitrogen) according to the
manufacturer’s instructions. The quality of RNA was evaluated
using spectrophotometry. The cDNA used for subsequent for PCR
was made using iScript (Bio-Rad Laboratories, Hercules, CA) and
Choice DNA Taq polymerase (Denville Scientific, Metuchen, NJ)
was used for subsequent PCR reactions. The expression of
VEGFR1 (Mm00438980_m1) and VEGFR2 (Mm00440099_m1)
was analyzed by quantitative real-time RT-PCR using an assay on
demand (Mm00440111_m1) from Applied Biosystems. GAPDH
(Applied Biosystems assay-on-demand) was used as an internal
reference gene to normalize input cDNA. Quantitative real-time
RT-PCR was performed in a reaction volume of 20 ml including
1 ml of cDNA, and each reaction was performed in triplicate. We
used the comparative Ct method to compute relative expression
values [60]. RNA isolated from murine brain endothelial cell line
(bEnd.3) was used a positive control.
Immunohistochemistry
Tissue was snap frozen in liquid nitrogen, embedded in OCT
media, and sectioned. Sections were fixed in acetone, briefly air-
dried and blocked with 20% Aquablock (East Coast Biologics,
North Berwick, ME) for 30–60 minutes. Primary antibodies were
used at a final concentration of 5–10 mg/ml and include: rat anti-
mouse endothelial cell (MECA-32, Developmental Studies Hy-
bridoma Bank, University of Iowa), rabbit anti-mouse CD31
(abcam, Cambridge, MA), rat anti-endomucin (sc-69495, Santa
Cruz Biotechnology, Santa Cruz, CA), goat anti-F4/80 (sc-26642,
Santa Cruz Biotechnology, Santa Cruz, CA), rat anti-CD68 (AbD
Serotec, Raleigh, NC), rat anti-neutrophil, 7/4 (MCA 7716, AbD
Serotec, Raleigh, NC), and rat anti-CD83 (Michel-19, BioLegend,
San Diego, CA). Primarily conjugated antibodies include PE-
labeled Gr1 (RB6-8C5), FITC-labeled CD11b (M1/70), Alexa
FluorH 488-labeled CD11c (N418) from Biolegend (San Diego,
CA), Alexa FluorH 488-labeled CD25 and Phycoerythrin-labeled
FoxP3 from eBioscience (San Diego, CA). Primary antibody was
incubated on sections for one hour at room temperature or
overnight at 4uC. Negative controls were performed by omitting
the primary antibody. Following washes, the appropriate fluor-
ophore conjugated secondary antibody was added (Jackson
Immunoresearch, West Grove, PA). Fluorescent slides were
cover-slipped using Prolong with DAPI (Invitrogen, Carlsbad,
CA). Sections were examined on a Nikon E600 microscope and
images captured with Photometrics Coolsnap HQ camera using
Elements Software. Fluorescent images were captured under
identical conditions (exposure time, high and low limits, and
scaling). Images were thresholded to exclude background signal
from secondary antibody alone.
ELISA/Electrochemiluminescence
Tumor lysates were made from orthotopic tumors by mincing
the tumor in lysis buffer. Protein content was assayed using BCA
assay (Pierce, Rockford, IL). Mouse total and active MMP-9,
serum IL-1b and IL-6 Quantikine Immunoassays were performed
according to manufacturer’s instructions (R&D Systems, Minnea-
polis, MN). Active TGFb levels were assessed using Promega
TGFb ELISA kit according to the manufacturer’s instructions
(Promega, Madison, WI). Electrochemiluminescence assays were
performed on biological triplicate samples using capture antibody
precoated 96-well multispot plates from Meso Scale Discovery
(MSD; Gaithersburg, MD). 75 mg–100 mg of total protein was
added to each well and incubated with shaking for 4 h at room
temperature. Specific protein levels were quantitated by adding
25 mlo f1mg/ml specific detection antibody labeled with MSD
SULFO-TAG reagent to each well and incubated with shaking for
1 h at room temperature. The plate was then washed three times
with PBS/0.05% Tween 20 and 150 ml of 2x read buffer was
added to each well. Plates were immediately read using the
SECTOR Imager 6000, and data were quantitated using
Discovery Workbench and SOFTmax PRO 4.0 software.
Statistics
Data were analyzed using GraphPad software (GraphPad Prism
version 4.00 for Windows; GraphPad Software, San Diego, CA,
www.graphpad.com). Results are expressed as mean6SEM.
Spearman rank correlations were used to assess associations
between immune parameters and cytokine levels. Data was
analyzed by t-test or ANOVA and results are considered
significant at p,0.05.
Supporting Information
Figure S1 Representative images of immunohistochemistry
staining for microvessel density and immune cell infiltration in
MDA-MB-231 model. Tumor sections were analyzed by immu-
nofluorescence using MECA-32, an endothelial cell marker (A),
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(C). Tumor sections were evaluated by immunofluorescence for
myeloid-derived suppressor cells defined as the number of cells
that express CD11b and Gr1 per 200X field (D). Representative
pictures of control (left column) and anti-VEGF treated tumors
that had an increase (middle column) and a decrease (right
column) in the indicated parameter. Total magnification, 200X;
except for Meca-32 staining (100X). Images were overlayed using
Elements software.
Found at: doi:10.1371/journal.pone.0007669.s001 (6.43 MB TIF)
Figure S2 Effect of anti-VEGF therapy on vascular parameters
in 4T1 tumors. Mice bearing established orthotopic 4T1 tumors
were treated for 3 weeks with control IgG (C44) mcr84 (250 mgi p
2x/week), GU81 (120 mg/day via osmotic pump), or sunitinib
(200 mg/day) (n=4/group). Tumor sections (n=4) were stained
for CD31 (A), endomucin (B) or VEGFR2 (C) by immunofluo-
rescence. Data are displayed as mean6SEM and represents 5
images per tumor and three tumors per group. Total magnifica-
tion 100X. The mean fluorescent area was determined with
Elements software. *, p,0.05; **, p,0.01 vs control by ANOVA.
Found at: doi:10.1371/journal.pone.0007669.s002 (0.38 MB TIF)
Figure S3 Effect of anti-VEGF therapy on immune cell
infiltration in the transgenic MMTV-PyMT breast tumor model.
(A) Treatment with 250 mg twice weekly of either control IgG or
mcr84, 120 mg daily GU81 or 200 mg daily sunitinib was initiated
when transgenic females were 52 days old (arrow) and continued
for 4 weeks (n=5/group). Tumor volumes were measured twice
weekly and mean tumor volume +/2 SEM is displayed. (B–D)
Tumor sections were analyzed by immunofluorescence using
MECA-32, an endothelial cell marker (B), macrophages
(CD11b+Gr1- cells) (C) and neutrophils (CD11b-Gr1+) (D). (E–
F) Tumor sections were evaluated by immunofluorescence for (E)
MDSCs, co-localization of CD11b+ and Gr1+ (F) Tregs, co-
localization of CD25+and FoxP3+. Data are displayed as
mean6SEM and represents 5 images per tumor and three tumors
per group. Total magnification, 200X, except for Meca-32
staining (100X). Images were overlayed and using Elements
software. *p=0.05, **p=0.01, ***p,0.001, ##p=0.01 vs
mcr84.
Found at: doi:10.1371/journal.pone.0007669.s003 (3.41 MB TIF)
Table S1 4T1 cells express VEGFR1 but not VEGFR2. RNA
isolated from murine (bEnd.3) endothelial cells and 4T1 cells was
used for qRT-PCR analysis of VEGFR1 and VEGFR2 and
normalized to GAPDH. The mean Ct (cycle threshold) value for
each target is displayed.
Found at: doi:10.1371/journal.pone.0007669.s004 (0.03 MB
DOC)
Table S2 Anti-VEGF therapy modulates intra-tumoral cytokine
levels in MDA-MB-231 human breast tumor xenografts. Mean
pg/mg total protein is displayed. N=3 tumors/group assayed in
duplicate at the one and four week time points. Values in italic
indicate cytokine levels that decreased significantly compared to
control; values in bold indicate cytokine levels that increased
significantly compared to control, all p,0.01 or p,0.001 by one-
way ANOVA, Bonferroni Multiple Comparison Test. n.d., not
detected.
Found at: doi:10.1371/journal.pone.0007669.s005 (0.05 MB
DOC)
Table S3 Anti-VEGF therapy modulates intra-tumoral and
serum cytokine levels in 4T1 murine breast tumor xenografts.
Mean pg/mg total protein if displayed. N=3 tumors/group
assayed in duplicate at the one and three week time points. Values
in italics indicate cytokine levels that decreased significantly
compared to control; values in bold indicate cytokine levels that
increased significantly compared to control, all p,0.01 or
p,0.001 by one-way ANOVA, Bonferroni Multiple Comparison
Test. n.d., not detected.
Found at: doi:10.1371/journal.pone.0007669.s006 (0.05 MB
DOC)
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